Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 1976-1983

  Becker, Silvan ^a   Markova, Boyka ^a   Wiewrodt, Rainer ^c   Hoffarth, Sandra ^a   Hähnel, Patricia S ^a   Pleiner, Sina ^a   Schmidt, Lars Hennig ^c   Breitenbuecher, Frank ^a   Schuler, Martin ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Apoptosis; Biomarker; Non small cell lung cancer; WWOX

Indexed keywords

COMPLEMENTARY DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL POPULATION; CELL SURVIVAL; CLONOGENIC ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSGENICS; TUMOR SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE WWOX;

EID: 81755173581     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822e59dd     Document Type: Article

References (29)

1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-566. (Pubitemid 47206930)
5. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALKrearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363:1727-1733.
6. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62-93.
7. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95-107.
8. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009;9:714-723.
9. Ludes-Meyers JH, Bednarek AK, Popescu NC, et al. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 2003;100:101-110. (Pubitemid 37467796)
10. Bednarek AK, Laflin KJ, Daniel RL, et al. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60: 2140-2145. (Pubitemid 30225175)
11. Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 2003;63:878-881. (Pubitemid 36231991)
12. Donati V, Fontanini G, Dell'Omodarme M, et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 2007;13:884-891. (Pubitemid 46340363)
13. Baykara O, Demirkaya A, Kaynak K, et al. WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC). Tumour Biol 2010;31:315-320.
14. Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 2007;104: 3949-3954. (Pubitemid 47181559)
15. Fabbri M, Iliopoulos D, Trapasso F, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 2005;102:15611-15616. (Pubitemid 41528104)
16. Urlinger S, Baron U, Thellmann M, et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000;97: 7963-7968. (Pubitemid 30460756)
17. Schmidt LH, Biesterfeld S, Kummel A, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res 2009;29:201-209.
18. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue.] Pathologe 1987;8: 138-140.
19. Fux R, Schwab M, Thon KP, et al. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11:4754-4760. (Pubitemid 41557195)
20. Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:7086-7092. (Pubitemid 350276892)
21. Zhang P, Ying L, Xu R, et al. Tumor-specific, hypoxia-regulated, WW domain-containing oxidoreductase-expressing adenovirus inhibits human non-small cell lung cancer growth in vivo. Hum Gene Ther 2010;21:27-39.
22. Qin HR, Iliopoulos D, Semba S, et al. A role for the WWOX gene in prostate cancer. Cancer Res 2006;66:6477-6481. (Pubitemid 44085599)
23. Iliopoulos D, Fabbri M, Druck T, et al. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 2007;13:268-274. (Pubitemid 46121879)
24. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435: 677-681. (Pubitemid 40825512)
25. Wesarg E, Hoffarth S, Wiewrodt R, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007;121:2387-2394. (Pubitemid 350022407)
26. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068-8073. (Pubitemid 33091591)
27. Aderca I, Moser CD, Veerasamy M, et al. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol 2008;49:373-383.
28. Chang NS, Doherty J, Ensign A, et al. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem 2005;280:43100-43108. (Pubitemid 43049276)
29. O'Keefe LV, Liu Y, Perkins A, et al. FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila. Oncogene 2005;24:6590-6596. (Pubitemid 41486642)